Vilon

Mechanism

Vilon is the smallest peptide in the Khavinson bioregulator series, consisting of just two amino acids, designed to restore thymus gland function and rejuvenate the immune system. The thymus gland shrinks with age, leading to weakened immunity, and Vilon helps reactivate the genes responsible for T-cell maturation and immune surveillance. It has been studied in elderly populations where it has shown the ability to reduce respiratory infections and improve immune markers.

Effects

**Immune System (Tier 3 — Khavinson Bioregulator Research):** Vilon is a synthetic dipeptide (Lys-Glu / KE) developed by Prof. Vladimir Khavinson as the minimal bioactive sequence derived from thymic peptides. Despite being only two amino acids, Khavinson's research proposes that this dipeptide has specific epigenetic regulatory activity — binding to particular DNA sequences in the promoter regions of genes involved in immune cell differentiation and proliferation. **Epigenetic Regulation (Tier 3):** Khavinson lab studies report that Vilon (KE dipeptide) interacts with the TTAGGG repeat sequence in DNA (telomeric and regulatory regions), potentially modulating gene expression in immune cells. Claimed effects include upregulation of genes involved in T-cell differentiation, IL-2 receptor expression, and cell cycle progression in lymphocytes. **Hematological (Tier 3):** In animal models and small human studies, Vilon administration was reported to normalize leukocyte counts in immunosuppressed states (post-radiation, post-chemotherapy). Proposed mechanism: stimulation of bone marrow progenitor cells toward lymphoid lineage differentiation.

Practitioner Guide

**Standard Protocol:** - Available as oral drops or capsules - Dose: 10-20mcg sublingual daily for 10-20 days, or as oral capsule - Cycle: repeat every 3-6 months - Often combined with other Khavinson bioregulators (crystagen, vladonix, endoluten) **Clinical Context:** - Vilon is the simplest peptide in the Khavinson bioregulator system — a dipeptide (Lys-Glu) - The concept that a dipeptide can have tissue-specific epigenetic effects is scientifically intriguing but not widely validated outside Khavinson's laboratory - Oral bioavailability of dipeptides is favorable — PepT1 transporter efficiently absorbs di/tripeptides intact **Honest Assessment:** - Evidence is primarily from Khavinson's own laboratory publications - Limited independent replication - The claim that a simple dipeptide can specifically regulate gene expression is extraordinary and requires extraordinary evidence - For practitioners seeking immune peptide support: thymosin alpha-1, thymalin, or even zinc-thymulin have substantially more clinical evidence - Vilon may be useful as an inexpensive, low-risk oral immune support, but should not replace evidence-based immune therapies for serious conditions

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human safety data during pregnancy. Immune-modulating peptide could affect maternal-fetal immune tolerance.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Immune-modulating effects on nursing infant unknown.
  Action: Do not use while breastfeeding.
• hard stop — Organ transplant recipient
  Vilon stimulates thymic function and T-cell maturation. Immune stimulation in transplant recipients may trigger graft rejection, even with adequate immunosuppression.
  Action: Absolutely contraindicated in organ transplant recipients.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Immune modulation may interfere with normal immune maturation.
  Action: Do not provide to individuals under 18.
• requires physician — Autoimmune disease
  Vilon enhances immune surveillance and T-cell function. In patients with autoimmune conditions, this may exacerbate autoimmune responses and trigger disease flares.
  Action: Requires specialist evaluation by immunologist or rheumatologist. Monitor autoimmune markers closely.

Research Summary

**Tier 2 — Russian Published Research:** - Khavinson laboratory: multiple publications showing Vilon (KE dipeptide) modulates gene expression in lymphocyte cultures - In vitro: Vilon increases proliferation of lymphocytes, enhances IL-2 production, upregulates CD markers - Animal studies: post-radiation immune recovery in rats treated with Vilon showed faster normalization of leukocyte counts - Small human studies in elderly: 10-day Vilon courses reported to improve T-cell counts and functional immune parameters **Tier 3 — Emerging/Theoretical:** - DNA interaction studies: Khavinson lab reports specific binding of KE dipeptide to TTAGGG sequences via molecular modeling and binding assays — mechanism for epigenetic regulation - Independent validation is limited — the concept of short peptide-DNA regulatory interactions is biologically novel and requires broader scientific scrutiny - Pharmacokinetics: dipeptides are absorbed via PepT1 transporter with high efficiency — oral bioavailability is biologically plausible - No Western clinical trials - Part of the broader Khavinson "peptide bioregulation" theory — a unique Russian school of biogerontology that has generated interest but limited Western adoption